Altered biodistribution of an antibody-enzyme conjugate modified with polyethylene glycol
1996

Modified Antibody-Drug Conjugate for Cancer Treatment

Sample size: 8 publication Evidence: moderate

Author Information

Author(s): EA Eno-Amooquaye, F Searle, JA Boden, SK Sharma, PJ Burke

Primary Institution: Cancer Research Campaign Laboratories, Department of Medical Oncology, Charing Cross Hospital, London, UK

Hypothesis

Does polyethylene glycol modification improve the selective retention of an antibody-enzyme conjugate in a xenograft model?

Conclusion

The study found that polyethylene glycol modification increases the concentration of the antibody-enzyme conjugate in tumors but also leads to higher levels in normal tissues.

Supporting Evidence

  • PEG modification increased the duration of the conjugate in circulation.
  • Modified conjugate showed higher tumor uptake compared to unmodified.
  • Statistical analysis indicated significant differences in biodistribution.

Takeaway

Scientists added a special coating to a cancer-fighting drug to help it stay in the body longer and work better at the tumor, but it also ended up in other places it shouldn't be.

Methodology

The study involved injecting modified and unmodified antibody-enzyme conjugates into mice with human colon cancer and measuring their distribution in various tissues over time.

Limitations

The study did not address the long-term effects of increased enzyme concentrations in normal tissues.

Participant Demographics

Inbred MF-I female athymic nude (nu/nu) mice, 2-3 months old.

Statistical Information

P-Value

<0.0001

Statistical Significance

p<0.0001

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication